Suven Life Sciences commences Phase 1 clinical trial for NCE SUVN-D4010

For treatment of Alzheimer's disease and other dementias

Suven Life Sciences announced that their NCE SUVN-D4010 has commenced Phase 1 clinical trial in USA. SUVN-D4010 is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist for the treatment of cognitive dysfunction associated with Alzheimer's disease and other dementias.

Suven submitted Investigational New Drug Application (IND) to US FDA to conduct Phase-1 clinical trial for Cognition in Alzheimer's Disease, under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA) which was assigned an IND number 126099.

This is the third compound from the Company's pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia, a high unmet medical need which has huge market potential globally.

The other two clinical stage compounds are, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031.

Powered by Capital Market - Live News